Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg Pages 273 - 280 ( 8 )
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
psoriasis,biologic therapy,t cell,cytokine,infliximab,etanercept,efalizumab,alefacept,adalimumab,tazarotene
, , Department of Dermatology,St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D,New York, NY 10025.